Home > Documents in Process > Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome. > print

001     281913
005     20251112111620.0
024 7 _ |a 10.1038/s41467-025-65882-x
|2 doi
024 7 _ |a pmid:41213934
|2 pmid
037 _ _ |a DZNE-2025-01255
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Huber, Hanna
|0 P:(DE-2719)9003257
|b 0
|e First author
|u dzne
245 _ _ |a Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1762942436_29014
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Diagnosing Alzheimer's disease (AD) in adults with Down syndrome (DS), a population with a high genetically determined risk of AD, remains challenging. In this large observational study including n = 2329 samples from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and euploid controls from the Sant Pau Initiative on Neurodegeneration (SPIN) with and without symptomatic AD, we investigate if the strong diagnostic performance of plasma p-tau217 observed in sporadic AD extends to the DS population. Plasma p-tau217 discriminated cognitively stable individuals with DS from those with AD dementia with an AUC of 0.96 (95% CI, 0.95-0.97), and from those with prodromal AD with an AUC of 0.90 (95% CI, 0.87-0.92). Amyloid β (Aβ) positive and Aβ negative individuals with DS were distinguished with an AUC of 0.95 (95% CI, 0.92-0.99). In this study, we demonstrate that plasma p-tau217 is highly accurate in detecting amyloid β positivity and predicting clinical progression in individuals with DS, outperforming other plasma biomarkers. These findings support its use as a reliable, noninvasive tool for early AD detection and management in individuals with DS.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
700 1 _ |a Arranz, Javier
|0 0000-0003-0891-1215
|b 1
700 1 _ |a Arslan, Burak
|b 2
700 1 _ |a Leuzy, Antoine
|b 3
700 1 _ |a Kittel, Oscar
|b 4
700 1 _ |a di Molfetta, Guglielmo
|0 0009-0001-5339-933X
|b 5
700 1 _ |a Benejam, Bessy
|b 6
700 1 _ |a Videla, Laura
|0 0000-0002-9748-8465
|b 7
700 1 _ |a Barroeta, Isabel
|b 8
700 1 _ |a Soriano, Laura Del Hoyo
|b 9
700 1 _ |a Maure-Blesa, Lucía
|0 0000-0001-5643-7971
|b 10
700 1 _ |a Rodríguez-Baz, Íñigo
|0 0000-0003-3039-9115
|b 11
700 1 _ |a Arriola Infante, José Enrique
|b 12
700 1 _ |a Illán-Gala, Ignacio
|b 13
700 1 _ |a Bejanin, Alexandre
|0 0000-0002-9958-0951
|b 14
700 1 _ |a Montoliu-Gaya, Laia
|0 0000-0001-7684-6318
|b 15
700 1 _ |a Lleó, Alberto
|0 0000-0002-2568-5478
|b 16
700 1 _ |a Carmona-Iragui, María
|b 17
700 1 _ |a Alcolea, Daniel
|0 0000-0002-3819-3245
|b 18
700 1 _ |a Blennow, Kaj
|0 0000-0002-1890-4193
|b 19
700 1 _ |a Zetterberg, Henrik
|0 0000-0003-3930-4354
|b 20
700 1 _ |a Fortea, Juan
|0 0000-0002-1340-638X
|b 21
700 1 _ |a Ashton, Nicholas J
|0 0000-0002-3579-8804
|b 22
773 _ _ |a 10.1038/s41467-025-65882-x
|g Vol. 16, no. 1, p. 9900
|0 PERI:(DE-600)2553671-0
|n 1
|p 9900
|t Nature Communications
|v 16
|y 2025
|x 2041-1723
856 4 _ |u https://pub.dzne.de/record/281913/files/DZNE-2025-01255.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/281913/files/DZNE-2025-01255.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9003257
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT COMMUN : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-30T07:48:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-30T07:48:07Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2024-01-30T07:48:07Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-01-30T07:48:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NAT COMMUN : 2022
|d 2025-01-02
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-02
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21